NEW YORK — Ultivue said on Tuesday that it has formed a comarketing alliance with omics contract research organization Sirona Dx focused on tissue-based spatial multiplexed immunophenotyping.
Under the terms of the deal, the companies will offer Ultivue's InSituPlex technology, which uses antibody-DNA barcoding and signal amplification for biomarker detection and analysis in tissue samples, along with Sirona Dx's ultra-high parameter, multiplexed imaging services.
Financial and other terms were not disclosed.
"Clients have relied on our leading expertise to develop and implement customized, high performance multiplexed imaging panels of up to 40 markers," Sirona Dx Chief Commercial Officer Andrew Brown said in a statement. "We can now harness Ultivue's powerful InSituPlex technology to rapidly develop robustly validated mid-plex panels of up to 12 markers, enabling our clients to accelerate their drug development programs with transformative biomarker capabilities."
Earlier this month, Cambridge, Massachusetts-based Ultivue struck a spatial multiplexed biomarker tools development alliance with Aignostics.